ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported record revenue growth and strong e-commerce performance, which are positive indicators. Despite some supply chain issues, management remains optimistic about growth, especially with the Niagen IV expansion and potential partnerships. The Q&A revealed uncertainties in the NO PARK study and NAD+ testing, but these were not major concerns. Overall, the positive revenue outlook and strong product development outweigh the minor uncertainties, suggesting a positive stock price movement in the near term.
Key Financial Performance
Revenue (Q4 2024) $29.1 million, a 37% increase year-over-year.
Net Income (Q4 2024) $7.2 million, a substantial increase from $0.1 million in the prior year period.
Gross Margin (Q4 2024) 62.5%, improved by 150 basis points compared to 61% in Q4 2023.
Cash Flow from Operations (2024) $12.1 million, up from $7.1 million in the prior year.
Total Net Sales (Full Year 2024) $99.6 million, a 19% growth year-over-year.
Net Income (Full Year 2024) $8.6 million, a turnaround from a net loss of $4.9 million for fiscal year 2023.
Selling and Marketing Expenses (Q4 2024) 29.9% of net sales, improved by 90 basis points compared to 30.8% in Q4 2023.
General and Administrative Expenses (Q4 2024) Decreased by $4.4 million, driven by a $3.5 million reversal of royalties and fees related to an agreement with Dartmouth.
Operating Income (Q4 2024) $7.1 million, compared to a $200,000 operating loss in Q4 2023.
Cash Balance (End of 2024) $44.7 million, with no debt.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launch: Launched Niagen Plus product line and introduced Niagen IV and injections at clinics through a compound pharmacy network.
Product Availability: Niagen IV is now available in about 500 clinics nationwide.
Market Expansion: Expansion of the sale of Niagen products and ingredients in new markets.
E-commerce Growth: E-commerce channel experienced robust organic growth with net sales of $17.3 million, a 30% increase year-over-year.
Operational Efficiency: Gross margins improved by 150 basis points to 62.5% due to changes in product mix and operational efficiencies.
Cost Management: Selling and marketing expenses decreased as a percentage of net sales, reflecting improved operational efficiency.
Strategic Shift: Company plans to change its name to better represent its evolution and strategic direction.
Regulatory Engagement: Initiated communication with the FDA for an investigational new drug application for NR in treating ataxia telangiectasia.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitive Pressures: The company faces increasing competition as more companies enter the NAD-boosting product market, some of which engage in misleading practices, infringe on patents, and make false claims.
Regulatory Issues: ChromaDex is actively communicating with the FDA regarding an investigational new drug application, indicating potential regulatory hurdles in the approval process for their products.
Supply Chain Challenges: The company experienced delays of 2 to 3 months in the availability of pharmaceutical-grade ingredients due to supply chain issues, although these have since been resolved.
Economic Factors: Global market conditions and economic factors could impact ChromaDex's business activities and financial results, as noted in their forward-looking statements.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Projected approximately 18% growth year-over-year in net sales for 2025, reflecting continued expansion in e-commerce and established partnerships.
R&D Investment: R&D expenses expected to increase year-over-year in absolute dollars, remaining stable at 6% of net sales to support NAD precursor development.
Company Name Change: Announcement of a company name change to better represent the evolution and strategic direction of ChromaDex.
Pharmaceutical Growth: Continued progress in the pharmaceutical-grade ingredient business, with Niagen IV and injections on pace for growth in the second half of 2025.
2025 Revenue Outlook: Expecting net sales of approximately $117 million, reflecting an 18% growth year-over-year.
Gross Margin: Anticipating a modest improvement in gross margins due to supply chain optimizations and cost-saving initiatives.
Selling and Marketing Expenses: Expected to increase in absolute dollars but remain stable as a percentage of net sales at approximately 29.6%.
General and Administrative Expenses: Expected increase of $5 million to $6 million due to investments in business growth and absence of royalty reversals.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: None
Dividend Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you talk about the stick packs a little bit, as far as give us a sense of pull-through on Amazon or your website and a sense of what’s the milligram size? And any comments as far as pricing?
A:It’s 300 milligrams per stick pack. It also has inulin in it. Sales of stick packs have begun to increase, and we expect to initiate more of a marketing campaign behind it in 2025.
Q:The 1.3 adjustment on the royalties for the fourth quarter, you expect – you said the second and final in the first quarter, that will also be 1.3 as well.
A:That’s not a royalty adjustment. That’s the Elysium settlement. The royalty adjustment relates to Dartmouth. We reversed $3.5 million in Q4 with regards to Dartmouth. That’s not going to reoccur.
Q:On the NO PARK study, should we expect a readout or some commentary from the company in the third quarter or the fourth quarter?
A:We really don’t know. It’s a double-blinded study. We expect them to share it with us, but we don’t know for sure that they will once they have the data compiled.
Q:Could you talk about the food grade Niagen segment sticking out because it’s been extremely strong in the back half of 2024?
A:Yes, we expect it to continue to grow. We’ve added a couple of other partners, and we expect the ingredient business to grow nicely in 2025.
Q:Could you just expand a little bit on the drivers of your strong e-commerce performance in the fourth quarter?
A:We’ve always done extremely well on Amazon, and we’ve seen a nice improvement in our Shopify performance.
Q:Was the growth driven by strong new customers, recurring? How would you characterize that?
A:There is a slight increase in recurring customers, but it’s mostly new to brand.
Q:Could you talk about the initial ramp of Niagen IV, where you would expect to end roughly in the number of clinics?
A:We had announced back in November, I think, 300 clinics. I think this morning, we announced that we’re up to around 500. Our expectation is we’ll be at least double that by the end of the year.
Q:How confident are you in your supply chain ability to keep up with demand?
A:I think there will always be risks. We’ve resolved the hiccups we had and expect to get back going in terms of sales.
Q:Any thoughts on how tariffs might potentially impact sourcing or parts of your international business?
A:It’s possible that tariffs will have a small impact on the Watson business and on the food grade – the pharma-grade Niagen business.
Q:Any other innovations that you’re able to talk about plan for the year?
A:We do plan to introduce 1 or 2 new formulations that are complementary to Tru Niagen.
Q:Is the food grade ingredient business hitting a tipping point with awareness?
A:This has been steadily going on now for several quarters. Our partners are doing quite well.
Q:Has the shortage of the IV product accelerated interest at all?
A:Initially, we saw a little bit of that, but the problem has been going on for a few months.
Q:What was the impact in the fourth quarter from the supply chain issues with the IV?
A:In the area of about $1 million a quarter, maybe even a little less.
Q:Can you comment on potential tailwinds in 2025 from Niagen IV uptake?
A:We think that’s one area with great upside potential for Tru Niagen.
Q:What are the implications if the Parkinson’s disease study reports positive data?
A:If it was just 5%, you’re talking about very, very dramatic significant numbers.
Q:Will there be a spin-off for drug approval?
A:If we were in that place, yes, we would do a spinout.
Q:Could you clarify on the G&A expectation for the year?
A:Yes, I do. It would be about $1 million to $2 million increase based on reported numbers.
Q:Is there going to be any effort to get back any prior paid and booked royalties on Dartmouth?
A:No, we’re not going to go after them for that.
Q:Is Niagen IV higher margin than the overall average?
A:Correct.
Q:Can you comment on the frequency of people doing Niagen IV?
A:We really don’t know about repeat users because we didn’t have material to supply to the clinics.
Q:Have you looked into partnerships with clinical labs for doing NAD+ testing?
A:We’re not very confident in the quality of the data that it would deliver.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the timing of the NO PARK study readout, stating they expect to receive data but cannot guarantee it will be shared publicly. Additionally, there was a lack of clarity on the frequency of Niagen IV users due to supply issues, and the response about potential partnerships for NAD+ testing was vague, indicating uncertainty about the quality of data that could be obtained.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA
NR treatment
Officer Fried
Plus
RD
Selling marketing
agreement Dartmouth
announcement
basis point
channel
conference today
credit loss
direction
dollar percentage
excellence
food grade
future
grade ingredient
grade pharmaceutical
income
issue
label
leader
mission
payment
pharmaceutical grade
provision
recovery
resource
reversal royalty
royalty fee
sale increase
settlement
supply chain
use NR
website
week
CDXC Transcript
ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Call Transcript
Positive3-5
The company reported record revenue growth and strong e-commerce performance, which are positive indicators. Despite some supply chain issues, management remains optimistic about growth, especially with the Niagen IV expansion and potential partnerships. The Q&A revealed uncertainties in the NO PARK study and NAD+ testing, but these were not major concerns. Overall, the positive revenue outlook and strong product development outweigh the minor uncertainties, suggesting a positive stock price movement in the near term.
Earnings call transcript: Chromadex’s Q4 2024 earnings beat forecasts, stock rises
Positive3-4
The earnings call shows strong financial performance with record revenues, significant net income growth, and improved margins. The e-commerce channel and NIAGEN ingredient sales have also seen substantial increases. While there are uncertainties in R&D outcomes, the overall financial health and strategic product launches suggest a positive outlook. The Q&A section did not reveal major concerns that would offset these positives. Despite the lack of a share repurchase program, the company's cash flow and debt-free status support a positive sentiment.
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
Positive11-1
The earnings call highlights strong financial performance with a 31% revenue increase and improved margins. Despite some risks like competitive pressures and regulatory challenges, the company shows a positive cash flow and no debt. The Q&A reveals plans for expansion and positive consumer response to Niagen. The lack of specific shareholder return plans is a slight negative. Overall, the positive financials and optimistic market strategy suggest a stock price increase, likely in the 2% to 8% range.
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
Positive8-8
The earnings call highlights strong financial performance with a 31% revenue increase and improved margins. Despite some risks like competitive pressures and regulatory challenges, the company shows a positive cash flow and no debt. The Q&A reveals plans for expansion and positive consumer response to Niagen. The lack of specific shareholder return plans is a slight negative. Overall, the positive financials and optimistic market strategy suggest a stock price increase, likely in the 2% to 8% range.
CDXC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
